Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Top Cited Papers
- 20 November 2013
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 76 (6), 908-916
- https://doi.org/10.1111/bcp.12114
Abstract
Apixaban is an oral, direct, factor-Xa inhibitor approved for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery and for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. This open label, parallel group study investigated effects of extremes of body weight on apixaban pharmacokinetics, pharmacodynamics, safety and tolerability. Fifty-four healthy subjects were enrolled [18 each into low (≤50 kg), reference (65-85 kg) and high (≥120 kg) body weight groups]. Following administration of a single oral dose of 10 mg apixaban, plasma and urine samples were collected for determination of apixaban pharmacokinetics and anti-factor Xa activity. Adverse events, vital signs and laboratory assessments were monitored. Compared with the reference body weight group, low body weight had approximately 27% [90% confidence interval (CI): 8-51%] and 20% (90% CI: 11-42%) higher apixaban maximum observed plasma concentration (Cmax) and area under the concentration-time curve extrapolated to infinity (AUC(0,∞)), respectively, and high body weight had approximately 31% (90% CI: 18-41%) and 23% (90% CI: 9-35%) lower apixaban Cmax and AUC(0,∞) , respectively. Apixaban renal clearance was similar across the weight groups. Plasma anti-factor Xa activity showed a direct, linear relationship with apixaban plasma concentration, regardless of body weight group. Apixaban was well tolerated in this study. The modest change in apixaban exposure is unlikely to require dose adjustment for apixaban based on body weight alone. However, caution is warranted in the presence of additional factors (such as severe renal impairment) that could increase apixaban exposure.This publication has 33 references indexed in Scilit:
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialThe Lancet, 2010
- In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction StudiesDrug Metabolism and Disposition, 2009
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementThe New England Journal of Medicine, 2009
- Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical SettingsAnnals of Pharmacotherapy, 2009
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to HumansDrug Metabolism and Disposition, 2008
- Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurrent Medical Research and Opinion, 2008
- Overweight, Obesity, and the Risk of Recurrent Venous ThromboembolismJAMA Internal Medicine, 2008
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging studyJournal of Thrombosis and Haemostasis, 2008
- Atrial fibrillation and obesity—results of a meta-analysisAmerican Heart Journal, 2008
- Mechanism-Based Concepts of Size and Maturity in PharmacokineticsAnnual Review of Pharmacology and Toxicology, 2008